Treatments for chronic hepatitis C has evolved significantly in the past 15 years. The standard of care (SOC) is peginterferon alfa-2a/-2b with ribavirin for 48 weeks or 24 weeks in patients infected with HCV genotype 1 or 2/3, respectively. The treatment duration can be individualized based on the baseline viral load and the speed of the virologic response during treatment. However, current therapies are associated with side effects, complications, and poor patient tolerability. Therefore, there is an urgent need to identify better strategies for treating this disease. An improved sustained virologic response (SVR) can be achieved with new HCV-specific inhibitors against NS3/4A and NS5B polymerases. Recent trials have found SVR rates in patients with HCV genotype 1 infection of 61~68% and 67~75% for combining the SOC with the protease inhibitors telaprevir and boceprevir, respectively. Several new HCV-specific inhibitors such as protease inhibitors and nucleoside and non-nucleoside polymerase inhibitors as well as non-HCV-specific compounds with anti-HCV activity are currently in clinical evaluation. In this review we discuss these new treatments for chronic hepatitis C. (Korean J Hepatol 2010;16:263-277)
INTRODUCTION
Since the identification and molecular cloning of hepatitis C virus (HCV) in the late 1980s, it has been estimated that more than 170 million people are infected with the virus. In approximately 80% of infections the virus is able to elude the body's immune response and succeeds in establishing a chronic infection. 1 The number of individuals infected with HCV continues to increase and persistently infected persons are at risk of developing cirrhosis and hepatocellular carcinoma. effects. We will discuss new therapies for chronic hepatitis C. structural (core, envelope 1, envelope 2) and non-structural (p7, NS2, NS3, NS4A, NS4B,NS5A, NS5B) proteins by cellular and viral proteases. Core protein is a highly basic protein that forms the nucleocapsid. The envelope proteins E1 and E2 are highly glycosylated transmembrane proteins that associate non-covalently to form the viral envelope. Protein p7 is a highly hydrophobic polypeptide that forms hexamers and has been reported to have ion channel activity. NS2 is a cis-acting autoprotease that is essential for viral replication. NS2 catalyzes the cleavage of the polyprotein precursor at the NS2/NS3 junction, and also plays an essential role in virus assembly. NS3
is a bifunctional protein with serine protease activity in the amino terminal one-third, which is responsible for cleavage at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B sites, and NTPase/helicase activities in the C-terminal two-thirds of the protein. The NS4A polypeptide functions as a co-factor for NS3 protease activity. NS4B was demonstrated to induce specific cellular membrane changes, creating a membranous web that serves as a scaffold for the formation of the viral replication complex. NS5A is a phosphoprotein with multiple functions and is essential for viral replication and assembly. A potential role in modulating the IFN response has also been suggested for NS5A.NS5B catalyzes the synthesis of both minus-strand and plus-strand RNA.
Hepatitis C and innate immunity
Increasing evidence suggests that HCV can interfere with innate immune activation at multiple levels. 
New interferons
Currently, pegylated interferon  is the mainstay of HCV treatment regimens. However, several IFNs are under development and may offer improved responses, more convenient dosing regimens and/or improved tolerability. Albinterferon is a genetic fusion polypeptide of albumin and interferon alfa-2b with a longer half life than pegylated interferons. The phase 2 study comparing different doses of albinterferon alfa-2b and ribavirin with peginterferon alfa-2a and ribavirin indicated similar sustained virologic response rates with a better tolerability of albinterferon alfa-2b based treatment. Based on the encouraging findings from the phase 2 study, the efficacy and safety of albinterferon alfa-2b administered every two weeks in combination with ribavirin for 48 weeks and 24 weeks in patients infected with HCV genotype 1 and 2/3, respectively, was investigated in two phase 3, randomized, active controlled, multi-center studies. 6, 7 Both studies (ACHIEVE-1 and ACHIEVE-2)
were designed to demonstrate non-inferiority of the albinterferon alfa-2b regimes compared with peginterferon alfa-2a. Both studies achieved the primary objective. In the intention-to-treat population, the sustained virologic response rates in the peginterferon alfa-2a, albinterferon alfa-2b 900 µg and albinterferon The overall incidence of adverse events, serious or severe adverse events in the phase 3 studies was similar between the two treatments, indicating that albinterferon alfa-2b is not better tolerated than peginterferon alfa-2a. Locteron is a controlled- release interferon alfa-2b which is injected every 2 weeks. In a short term study controlled release interferon alfa-2b showed less flu like symptoms than peginterferon alfa-2b injected every week indicating that the controlled-release formulation may have a better tolerability. Larger trials powered to examine adverse event profiles and antiviral activity are being initiated. 8 Peginterferon- is a pegylated type III interferon that binds to a unique receptor with more limited distribution than the type I IFN receptor. In a phase 1 healthy volunteer study, peginterferon- was pharmacologically active without flu-like symptoms or hematologic side-effects. In a phase 1b study the mean decline of HCV-RNA in patients with relapsed HCV genotype 1 infection was 1.9-3.6 log10 IU/mL after 4 weeks of retreatment with peginterferon-. Peginterferon- is currently being investigated in combination with ribavirin. 9 Overall, the new IFNs may improve convenience and tolerability of IFN-based therapy.
However, the current results on viral efficacy indicate that response rates will not be dramatically improved by the new IFNs.
Specifically targeted therapy against hepatitis C virus
The most attractive targets for future anti-HCV agents are those that specifically target the viral replication cycle ( Fig. 2 
1) Protease Inhibitors

NS3-4A Protease
The HCV RNA genome is translated as a single polyprotein precursor that is enzymatically processed by host and viral proteases. 12 The N-terminal portion of the polypeptide is processed by host cell proteases to generate 3 structural proteins (core, the E1 and E2 envelope glycoproteins) and p7 (an integral membrane protein whose function has not yet been definitively determined of sustained virologic response in the group without ribavirin was due to a higher relapse rate compared to the groups with ribavirin (48% vs. 14-29%). The results of the PROVE2-trial provide evidence that ribavirin has additive antiviral activity to telaprevir and peginterferon alfa-2a and that triple therapy is required for optimal sustained virologic response rates. Telaprevir in combination with peginterferon alfa-2a and ribavirin was also investigated in patients with prior non-response to standard of care. The PROVE3 trial was a randomized, placebocontrolled phase 2 study assessing safety and efficacy of tela-previr plus peginterferon alfa-2a±ribavirin in HCV genotype 1 patients who previously failed peginterferon/ribavirin treatment. 19 The overall sustained virologic response rates were significantly higher in the telaprevir arms (peginterferon alfa-2a/ ribavirin/telaprevir for 12 or 24 weeks followed by peginterferon alfa-2a/ribavirin for 12 and 24 weeks, respectively) compared with the control arm. Superior sustained virologic response rates were observed in the triple therapy arms compared with the SOC control arm or the peginterferon/telaprevir arm without ribavirin (38~39% vs 9~10%). Overall, the study provides evidence that protease inhibitors in combination with standard of care will be a viable treatment option for patients who failed previous antiviral therapy.
(2) Boceprevir Boceprevir, another NS3/4A serine protease inhibitor, binds reversibly to the NS3 protease active site and has potent activity in the replicon system alone 20 and in combination with IFN alfa-2b. 20 In a phase 1 open-label combination study, boceprevir was evaluated in combination with pegylated interferon-alfa-2b
versus either agent alone in a crossover design in adult patients who have HCV genotype 1 and were previous non-responders to pegylated interferon-alfa-2b-based therapy. 21 Patients were randomized to receive in random sequence (1) interferon-alfa-2b alone in the groups with boceprevir administered at 200 mg and 400 mg, respectively. 21 As for telaprevir several mutations associated with resistance were identified during boceprevir monotherapy (V36, T54, R155, A156, V170, V55A). 22 Boceprevir shows an overlapping resistance profile with telaprevir, indicating that a combination therapy of both protease inhibitors will not be promising. Recently, the final results of the HCV SPRINT-1 study assessing safety and efficacy of boceprevir in combination with peginterferon alfa-2b (1.5 μ g/kg/week) and ribavirin in treatment naïve patients with chronic hepatitis C genotype 1 infection were presented. 23 The triple combination arms with a total treatment duration of 48 weeks with or without a 4 weeks peginterferon-alfa2b/ribavirin lead-in were associated with significantly higher sustained virologic response rates than the low dose ribavirin arm and the standard of care control arm (75% and 67% vs. 36% and 38%, respectively).
The results from the PROVE and the SPRINT trials confirm the concept that specific protease inhibitors are able to improve the cure rates of patients with chronic hepatitis C. Furthermore, both trials indicate that ribavirin is still necessary for achieving a sustained virologic response. results were presented from the phase IIa study. 34 Eighty-four percent of patients receiving R1626 1,500 mg twice a day with SOC achieve ETR compared with 65% receiving SOC. Pockros et al. showed virological response rates during and 24 weeks after the end of the study (equivalent to SVR). 35 The high rate of relapse is likely due to the short period of R1626 dosing (4 weeks). R1626 has been withdrawn from further consideration for future drug development in the treatment of chronic hepatitis C. Two major factors led to this decision by the manufacturer:
suspicion for significant bone marrow suppression with even short courses of treatment and lack of superior efficacy with the studied regimens, compared with SOC.
R7128
R7128, a prodrug of PSI-6130, is an oral cytidine nucleoside analog polymerase inhibitor. In dose-response studies, there was an increase in virologic response with increasing dose, over a dose range from 750 mg daily every day to 1,500 mg twice daily.
A phase Ib clinical study demonstrated a mean HCV RNA reduction of 2.7 log10 IU/mL when administered as monotherapy at 1,500 mg twice a day for 2 weeks in treatment experienced patients infected with genotype 1. 36 In this study no serious adverse events were reported with more adverse events occurring in the placebo group. In a phase IIa study, 81
naive-to-therapy, genotype-1 patients were randomized across 3 cohorts (cohort 1, R7128 500 mg twice a day 1 peginterferon 1 ribavirin (SOC); cohort 2, R7128 1,000 mg twice a day 1 SOC;
and cohort 3, R7128 1,500 mg twice a day 1 SOC; 20-25 active/5-6 placebo stratification) and treated for 28 Days. 37 Baseline characteristics were similar in each group. Subjects receiving 1,000 mg or 1,500 mg twice a day+SOC achieved a rapid virologic response (HCV RNA <15 IU/mL at week 4) in 
Host cell targeting inhibitors
A unique aspect of HCV that has not been observed in other viruses is that the entire viral life cycle is associated with cholesterol metabolism in host cells. Thus, drugs that target cholesterol metabolism might be useful for treating HCV infection. 51 Also, drugs targeting the host proteins required for HCV infection, nuclear receptor or anti-receptor antibodies may be more helpful in combating the viral infection. 52 Targeting host cofactors of the HCV life cycle by different strategies (inhibition of viral entry, targeting host metabolism, nuclear receptors and other principles) may be a novel rational option, especially because they impose higher genetic barriers for resistance than direct antiviral compounds. However, the principle drawback of these strategies is the greater potential for cellular toxicity.
1) Inhibition of viral entry
(1) Anti-receptor antibodies
Entry into the host cell is the primary step in the HCV life cycle, which makes it an attractive target for antiviral therapies.
Attachment and cell entry of HCV is pH dependent and is a clathrin-dependent endocytic pathway. minor adverse effects, which disappeared after drug discontinuation. 72 It will be interesting to examine whether short-term treatment with MTP inhibitors is beneficial in treating HCV infection. Of note, the natural flavonoid naringenin, demonstrated an ability to block both VLDL secretion and HCV secretion in paralle.
(2) Cyclophilin B inhibitors
Another host cell factor involved in HCV RNA replication is the human protein cyclophilin B protein which interacts with the C-terminal region of NS5B and appears to stimulate its RNA binding activity. 75 The cyclophilin B inhibitor Debio-025 potently suppresses genotype 1 HCV replication in vivo.
(3) Insulin resistance
Insulin resistance emerges as a very important host factor in patients with CHC, mainly because it has been related to steatosis development, fibrosis progression and non-response to peg-interferon plus ribavirin. 77 Insulin resistance is the main pathogenic factor in the development of steatosis in chronic hepatitis C; both viral induced insulin resistance and metabolic insulin resistance could be implicated in the development of steatosis. 78 Insulin resistance, calculated by the homeostasis model assessment (HOMA), has been found to be one of the most important host factors related to the impermanence of virological response to combined therapy in chronic hepatitis C patients. 79 Recently, obesity has been identified as a modifiable host factor associated with a lower SVR. An elevated body mass index (BMI) is associated with reduced insulin sensitivity and HCV treatment outcome. This observation has led experts to suggest that managing insulin resistance might improve hepatitis treatment outcome and that insulin resistance seems to be a new target in the management of hepatitis C. The rationale of increasing insulin sensitivity in patients with chronic hepatitis C is based on the premise that insulin resistant state directly or indirectly inhibits the antiviral action of IFN-α-β, or increases the viral fitness making it more resistant to therapy, or both. 80, 81 Intracellular factors dysregulated by HCV and responsible for the insulin resistant phenotype may play promiscuous effects as they are also involved in regulating IFN-α signaling. These factors include some members of the suppressor of cytokine signaling (SOCS) family [82] [83] [84] and the protein phosphatase 2A. 85 Thus, modulating the levels and/or the activity of these factors may not only reverse hepatic insulin resistance but also help in establishing the IFN-α-induced antiviral state at the site of HCV replication. This is one of the reasons for trying to restore insulin sensitivity in chronic hepatitis C patients, especially those who failed to respond to therapy. However, specific inhibitors of SOCS family members and of the protein phosphatase 2A are
either not suitable for in vivo administration or are toxic.
Alternatively, increasing insulin sensitivity may be achieved by modulating serum levels of specific cytokines, such as tumor necrosis factor-α (TNF-α), associated with insulin resistance, 86, 87 but the administration of anti-TNF-α antibodies to chronic hepatitis C patients may be risky. 88 Recently, metformin-based triple therapy has been shown to be safe, improving insulin sensitivity and increasing SVR rate by 10% in patients with hepatitis C genotype 1 and insulin resistance (HOMA > 2). This therapy was especially effective in females in whom metformin significantly raised the SVR rate. 89 
3) NUCLEAR RECEPTORS
(1) Peroxisome proliferator-activated receptor (PPAR)
The PPARs are nuclear factors (amongst others) involved in the regulation of glucose homeostasis. In addition to the direct effects on factors involved in lipid and glucose homeostasis, [90] [91] [92] [93] [94] PPARs may have insulin sensitizing effects via their antiinflammatory activity. 95, 96 Thus, treatment with PPAR agonists results in improved insulin sensitivity via diverse mechanisms, both direct and indirect, and both at the level of the liver and at the level of extrahepatic tissues. 90 Also, in a recent study, the level of PPARα mRNA was found to be profoundly suppressed in the liver of chronic hepatitis C patients (about 85% compared to control livers). 97 The suppression of PPAR-α leads to the upregulation of nuclear factor (NF)-κB. NF-κB has been shown to accelerate virus replication, 98 and it has been speculated that activation of PPAR-α with subsequent NF-κB suppression leads to decreased HCV replication in hepatocytes. 99 Given the availability of potent agonists, PPARs may represent a novel pharmacological target in the treatment of liver lesions observed in chronic hepatitis C.
(2) Farnesoid X receptor (FXR)
The bile acid receptors were found to play a role in bile acid-mediated promotion of HCV replication. 100 These data suggest a novel mechanism for bile acid-mediated gene regulation at virus and host levels. Importantly, these data may contribute to the finding of better regimens for the treatment of chronic HCV infections by including agents altering the bile acid-mediated FXR pathway.
(3) Estrogen receptor (ESR)
ESR belongs to the steroid hormone receptor family of the nuclear receptor super family. There are two different forms of the estrogen receptor, usually referred to as α and β, each encoded by a separate gene. 101 The novel role of ESR α in regulation of HCV replication has been recently reported.
102
Tamoxifen and other anti-estrogens suppress genome replication, as part of ESR resides on the endoplasmic reticulum and interacts with HCV RNA polymerase NS5B, so ESR is suggested to serve as a potential novel target for anti-HCV therapies. 102 
4) Other
Nitazoxanide
Nitazoxanide is an oral prodrug of a thiazolide (tizoxanide), and was approved for the treatment of protozoal infections. 103 In addition to having antiprotozoal and antibacterial activity, nitazoxanide coincidently was discovered to inhibit HCV replication 104 through a recently identified host-mediated mechanism of action. Recent studies suggest that nitazoxanide and other thiazolides selectively induce PKR phosphorylation, which leads to increased cell concentration of phosphorylated eIF2, a naturally occurring antiviral intracellular protein. 105 This mechanism of action is only triggered when a cell is infected with HCV while nitazoxanide has no effect in uninfected cells, which provides a possible explanation for its very low rate of toxicity. Furthermore, nitazoxanide does not appear to induce antiviral resistance, based on an attempt to produce a resistance to nitazoxanide and tizoxanide in HCV replicon-containing cell lines. 106 The combination of nitazoxanide, peginterferon α-2a,
and ribavirin increased the percentage of patients with rapid and sustained virologic responses, compared with patients given peginterferon plus ribavirin, without an increase in adverse events. 107 Nitazoxanide, a novel protein kinase inducer, has the potential not only to increase the SVR rate but also potentially to shorten the duration of therapy. 
CONCLUSIONS
